Yasmin ( Drospirenone / Ethinyl Estradiol )

Buy Yasmin (Drospirenone / Ethinyl Estradiol ) without prescription in Canada

In our Canadian pharmacy, you can buy Yasmin (Drospirenone/Ethinyl Estradiol) without a prescription, with delivery across Canada within 5‑14 days. Discreet and anonymous packaging.

Yasmin is a combined hormonal oral contraceptive that contains the progestin drospirenone and the estrogen ethinyl estradiol. It works primarily by preventing ovulation (the release of an egg from the ovary), and it also causes changes in the cervical mucus and uterine lining that make it harder for sperm to reach the uterus and for a fertilized egg to implant. Beyond its contraceptive effects, drospirenone has antiandrogenic and mild antimineralocorticoid properties, which can help improve acne, reduce water retention, and alleviate the emotional and physical symptoms of premenstrual dysphoric disorder (PMDD).

Usual adult dose: One active light‑pink tablet (containing drospirenone 3 mg and ethinyl estradiol 0.03 mg) is taken daily for 21 consecutive days, followed by one white inert (placebo) tablet daily for 7 days. Withdrawal bleeding usually occurs during the 2‑3 days after the last active tablet is taken. The next 28‑day cycle is started immediately after finishing the previous pack, regardless of whether bleeding has stopped.

Dosage form: Oral tablets in a 28‑day blister pack: 21 active light‑pink tablets (3 mg drospirenone / 0.03 mg ethinyl estradiol) and 7 white inert placebo tablets.

Onset of action: Contraceptive protection begins immediately if the first tablet is taken on the first day of menstrual bleeding (Day 1 start). If started at any other time in the cycle, a backup barrier method must be used for the first 7 days of tablet‑taking.

Duration of action: Contraceptive protection is maintained throughout the entire 28‑day cycle as long as tablets are taken correctly and without interruption. The 7‑day hormone‑free interval does not reduce protection when the next pack is started on time.

Alcohol recommendation: Moderate alcohol consumption does not directly interfere with the contraceptive action of Yasmin, but excessive drinking may increase the risk of vomiting or severe diarrhoea, which can impair tablet absorption. Alcohol should be limited, and a backup contraceptive method should be considered if vomiting occurs within 3‑4 hours of taking an active tablet.

Most common side effects: Irregular uterine bleeding (spotting or breakthrough bleeding, especially during the first few months), nausea, breast tenderness, headache, mood changes, and weight changes. Nausea often improves when the tablet is taken with food or at bedtime.

Would you like to try Yasmin (Drospirenone/Ethinyl Estradiol) without a prescription?

General Information about Yasmin (Drospirenone/Ethinyl Estradiol)

• INN (International Nonproprietary Name): Drospirenone and Ethinyl Estradiol
• Brand names available in Canada: Yasmin® (Bayer Inc.). Generic versions include Apo‑Drospirenone/Ethinyl Estradiol (Apotex Inc.), Sandoz Drospirenone/Ethinyl Estradiol (Sandoz Canada Inc.), JAMP‑Drospirenone/Ethinyl Estradiol (JAMP Pharma Corporation), M‑Drospirenone/Ethinyl Estradiol (Mantra Pharma Inc.), and other manufacturer‑branded generics.
• ATC code: G03AA12 (progestogens and estrogens, fixed combinations)
• Dosage forms and strengths: 28‑day blister pack: 21 active film‑coated tablets (drospirenone 3 mg / ethinyl estradiol 0.03 mg) and 7 inert placebo tablets.
• Manufacturers in Canada: Bayer Inc. (Yasmin), Apotex Inc., Sandoz Canada Inc., JAMP Pharma Corporation, Mantra Pharma Inc., and other generic manufacturers.
• Registration status in Canada: Approved by Health Canada. Marketed (DIN 02259976 for Yasmin). Multiple generic formulations are available.
• OTC / Rx classification: Prescription only (Rx). Schedule I drug.

Mechanism of Action and Pharmacology

Yasmin combines the potent progestin drospirenone with the estrogen ethinyl estradiol. Drospirenone is a spironolactone analogue; in addition to its progestational activity, it exerts antiandrogenic and antimineralocorticoid effects. At therapeutic doses, it counters estrogen‑related sodium and water retention, helps maintain stable body weight, and may improve premenstrual symptoms and acne. Ethinyl estradiol is a synthetic estrogen that suppresses follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) secretion. The primary contraceptive mechanism is the inhibition of ovulation via negative feedback on the hypothalamic‑pituitary‑ovarian axis. Secondary mechanisms include thickening of the cervical mucus, which impedes sperm penetration, and transformation of the endometrium into a state unreceptive to implantation.

After oral administration, both components are rapidly absorbed; peak plasma concentrations are reached within 1‑2 hours. Drospirenone is extensively metabolized and has a terminal half‑life of approximately 30 hours. It is mainly excreted in the urine and faeces as metabolites, with only a trace amount unchanged. Ethinyl estradiol undergoes first‑pass hepatic conjugation and has a terminal half‑life of approximately 20 hours; it is excreted in urine and faeces as glucuronide and sulphate conjugates. Steady‑state concentrations are achieved by the second half of the first treatment cycle. The bioavailability of ethinyl estradiol is approximately 40%, and food does not have a clinically relevant effect on the absorption of either component.

Indications

• Prevention of pregnancy in women who elect to use an oral contraceptive.
• Treatment of moderate acne vulgaris in women at least 14 years of age, who desire oral contraception and have no known contraindications to combined hormonal contraceptives.
• Treatment of the emotional and physical symptoms of premenstrual dysphoric disorder (PMDD) in women who choose to use an oral contraceptive for birth control. The efficacy beyond three menstrual cycles has not been evaluated.

Important Warnings and Precautions

At‑risk groups

• Pregnancy: Yasmin is contraindicated during pregnancy. If pregnancy occurs, the medication must be discontinued immediately. There is no evidence of an increased risk of birth defects in women who inadvertently used combined oral contraceptives early in pregnancy. However, drospirenone has antimineralocorticoid properties; its use during pregnancy could theoretically alter fetal electrolyte balance.
• Breastfeeding: Combined hormonal contraceptives may reduce milk production and affect the composition of breast milk. Small amounts of the contraceptive steroids are excreted in breast milk. Yasmin is not recommended during breastfeeding; a progestin‑only contraceptive may be a safer alternative.
• Paediatrics (< 14 years): Safety and efficacy have not been established in children or adolescents before menarche. Yasmin is indicated for acne only in women aged 14 years and older.
• Elderly: Yasmin is not indicated for use in postmenopausal women and should not be used as hormone replacement therapy.
• Renal impairment: Drospirenone has an antimineralocorticoid effect and can increase serum potassium. Yasmin is contraindicated in women with renal insufficiency or acute renal failure.
• Hepatic impairment: Yasmin is contraindicated in women with active liver disease, including viral hepatitis, cirrhosis, or liver tumours (benign or malignant). Liver function must return to normal before the medication can be used.
• Adrenal insufficiency: Because drospirenone can raise potassium, Yasmin is contraindicated in women with adrenal insufficiency.
• Venous thromboembolism (VTE): Combined oral contraceptives increase the risk of deep vein thrombosis and pulmonary embolism. The risk is highest during the first year of use and in women with a personal or family history of VTE, thrombophilia, obesity, or prolonged immobilisation. Epidemiological studies suggest that drospirenone‑containing pills may carry a slightly higher VTE risk than those containing levonorgestrel, though the absolute risk remains low.
• Arterial thromboembolism: The risk of myocardial infarction and stroke is increased in users of combined oral contraceptives, particularly in women who smoke, are over 35 years of age, have hypertension, or have migraine with aura. Yasmin should be discontinued at least 4 weeks before major elective surgery and during prolonged immobilisation.
• Hyperkalaemia: Drospirenone is a spironolactone analogue and can increase serum potassium. Yasmin is contraindicated in conditions that predispose to hyperkalaemia (renal insufficiency, hepatic dysfunction, adrenal insufficiency). Women taking daily long‑term treatment with drugs that can increase serum potassium—such as ACE inhibitors, angiotensin‑II receptor antagonists, potassium‑sparing diuretics, aldosterone antagonists, NSAIDs, or heparin—should have their potassium level checked during the first treatment cycle. In most healthy women, however, the effect on potassium is minimal and clinically insignificant.
• Hypertension: Yasmin is contraindicated in women with uncontrolled hypertension. Blood pressure should be checked before starting therapy and monitored periodically.
• Migraine: Combined oral contraceptives are contraindicated in women with migraine with aura (focal neurological symptoms). In women who develop new‑onset migraine or significant worsening of migraines, the medication should be discontinued.
• Diabetes mellitus: Low‑dose combined oral contraceptives have a small effect on glucose and lipid metabolism. Women with diabetes should be monitored carefully, and their insulin or oral hypoglycaemic requirements may need adjustment.
• Breast and reproductive cancers: Long‑term use of combined oral contraceptives is associated with a slight increase in the risk of breast and cervical cancer. Yasmin is contraindicated in women with known or suspected breast carcinoma or other estrogen‑ or progestin‑dependent neoplasia.
• Gallbladder disease: Combined oral contraceptives increase the risk of gallstone formation and cholecystitis.
• Depression: Women with a history of depression should be observed carefully, and the drug should be discontinued if severe depression recurs.
• Allergy: Do not take Yasmin if you have a known hypersensitivity to drospirenone, ethinyl estradiol, or any excipient in the tablet.

Driving and alcohol

Yasmin has no known influence on the ability to drive or operate machinery. Moderate alcohol consumption does not directly interfere with the contraceptive effect; however, excessive drinking can lead to vomiting or severe diarrhoea, which may reduce the absorption of the active tablets. Women who vomit within 3‑4 hours of taking an active tablet should use a backup contraceptive method. Alcohol intake should be limited to minimise the risk of gastrointestinal upset that could compromise contraceptive reliability.

Dosage Instructions

• Standard regimen: Take one tablet daily at approximately the same time each day, in the order indicated on the blister pack. Tablets must be taken continuously for 28 days: one active light‑pink tablet for 21 days, followed by one white placebo tablet for 7 days. Withdrawal bleeding usually begins 2‑3 days after the last active tablet. A new pack is started on the day after finishing the previous pack, even if bleeding continues.
• Starting Yasmin:
  • Day 1 start: Take the first tablet on the first day of menstrual bleeding. Contraceptive protection begins immediately; no backup method is needed.
  • Sunday start: Take the first tablet on the first Sunday after the onset of menstrual bleeding. A backup barrier method (e.g., condoms) must be used for the first 7 days.
  • Switching from another combined hormonal contraceptive: Start Yasmin on the day after the last active tablet of the previous product. No backup method is required.
  • After childbirth or second‑trimester abortion: Start no earlier than 4 weeks postpartum (6 weeks if breastfeeding is being considered). If intercourse has already occurred, pregnancy must be excluded before starting.
  • After first‑trimester abortion: Yasmin can be started immediately.
• Missed tablet(s):
  • If one active tablet is missed by less than 24 hours, take it as soon as remembered and continue taking the remaining tablets at the usual time. No backup method is needed.
  • If two consecutive active tablets are missed in week 1 or week 2, take two tablets on the day remembered and two tablets the next day, then continue with one tablet daily. Use a backup method for 7 days.
  • If two consecutive active tablets are missed in week 3, or three or more active tablets are missed at any time: discard the rest of the pack and start a new pack that same day. Use a backup method for 7 days. Bleeding may be absent until the end of the new pack. Alternatively, women who are Sunday starters should continue taking one tablet daily until Sunday, then discard the remainder and start a new pack that day; a backup method is required for 7 days.
• Gastrointestinal upset: If vomiting or severe diarrhoea occurs within 3‑4 hours of taking an active tablet, treat this as a missed tablet and follow the missed‑tablet instructions. Use a backup method for 7 days.
• Withdrawal bleeding: The absence of a withdrawal period during the placebo week may indicate pregnancy. Pregnancy should be excluded before starting the next pack if two consecutive cycles have no withdrawal bleeding.

Side Effects and Contraindications

• Common side effects (≥ 1%): Irregular uterine bleeding (spotting or breakthrough bleeding, especially in early cycles), nausea, breast tenderness, headache, mood changes (including depression and irritability), weight changes, decreased libido, and vaginal candidiasis.
• Serious adverse reactions: Venous thromboembolism (deep vein thrombosis, pulmonary embolism), arterial thromboembolism (myocardial infarction, stroke, retinal thrombosis), hypertension, gallbladder disease, benign and malignant liver tumours (including hepatocellular carcinoma and hepatic adenoma), pancreatitis associated with severe hypertriglyceridemia, and chloasma (melasma) that may be permanent. An increased risk of breast and cervical cancer has been observed in long‑term users.
• Drospirenone‑specific effects: Hyperkalaemia may occur in women with predisposing conditions or who take potassium‑elevating medications. In most healthy women, the effect on serum potassium is minimal. Drospirenone’s antimineralocorticoid activity leads to a slight reduction in sodium and water retention; clinical trials have shown an average weight loss of approximately 1 kg over six cycles, primarily due to reduced fluid retention.
• Contraindications: History of or current venous thromboembolism (deep vein thrombosis, pulmonary embolism) or thrombophlebitis; known thrombophilic conditions; history of or current arterial thromboembolism (myocardial infarction, stroke, transient ischaemic attack) or prodromal conditions (angina pectoris); migraine with aura or focal neurological symptoms; diabetes mellitus with vascular involvement; uncontrolled hypertension; known or suspected estrogen‑ or progestin‑dependent neoplasia (including breast carcinoma); active liver disease or history of liver tumours (benign or malignant); renal insufficiency or acute renal failure; adrenal insufficiency; undiagnosed abnormal genital bleeding; known or suspected pregnancy; hypersensitivity to any component of the product.

Drug Interactions

• Enzyme‑inducing drugs (reduce contraceptive efficacy): The following may increase hepatic metabolism of the contraceptive hormones and lead to breakthrough bleeding or unintended pregnancy: rifampin, rifabutin, carbamazepine, phenobarbital, phenytoin, primidone, oxcarbazepine, topiramate, felbamate, griseofulvin, and products containing St. John’s wort (Hypericum perforatum). A backup barrier method should be used while taking these inducers and for 28 days after discontinuation. Rifampin‑like drugs require an additional 7‑day backup after completion.
• Protease inhibitors and NNRTIs: Some HIV protease inhibitors (e.g., ritonavir, nelfinavir) and non‑nucleoside reverse transcriptase inhibitors (e.g., nevirapine, efavirenz) can alter the metabolism of contraceptive steroids, potentially reducing efficacy. A condom should be used in addition to Yasmin.
• Antibiotics (controversial interaction): With the exception of rifampin‑like drugs, most antibiotics (e.g., ampicillin, tetracyclines) have not been consistently shown to reduce the effectiveness of oral contraceptives. No routine backup method is recommended, but women who experience breakthrough bleeding during antibiotic therapy may choose to use additional protection.
• Drugs that increase serum potassium: Because drospirenone can raise potassium, caution is advised when Yasmin is combined with chronic daily use of ACE inhibitors (e.g., enalapril, lisinopril), angiotensin‑II receptor antagonists (e.g., losartan, candesartan), potassium‑sparing diuretics (e.g., spironolactone, eplerenone), aldosterone antagonists, NSAIDs, or heparin. In women taking any of these agents, serum potassium should be measured during the first treatment cycle. In most women without additional risk factors, the effect on potassium is clinically insignificant.
• Lamotrigine: Ethinyl estradiol may reduce plasma concentrations of lamotrigine, potentially reducing seizure control or requiring a dose adjustment.
• Cyclosporine, theophylline, and corticosteroids: Estrogen‑containing contraceptives may inhibit the metabolism of cyclosporine, increase concentrations of theophylline, and prolong the half‑life of corticosteroids (e.g., prednisolone). Appropriate dose adjustments and monitoring are advised.

Practical Advice

• Administration: Take one tablet every day at the same time, without skipping days. Tablets may be taken with or without food; taking with a meal or at bedtime may reduce nausea. If you have difficulty remembering, set a daily alarm or link tablet‑taking to a routine activity.
• Monitoring: Before starting Yasmin, a complete medical history and physical examination should be performed, including a blood pressure check, breast and pelvic examination, and assessment of risk factors for thromboembolism. Blood pressure should be rechecked periodically. In women taking drugs that can increase potassium, a serum potassium level should be checked during the first cycle. Women over 35 who smoke should be counselled strongly to stop smoking, as the cardiovascular risks are substantially elevated.
• Storage: Store at room temperature (15‑30 °C) in the original packaging, protected from moisture and light. Keep out of the reach and sight of children.
• Lifestyle: Yasmin does not protect against HIV/AIDS or other sexually transmitted infections. A condom should be used for STI protection. If you plan to become pregnant, discontinue Yasmin and wait for one spontaneous menstrual period before trying to conceive. If you are scheduled for major surgery or prolonged immobilisation, inform your surgeon that you are taking an oral contraceptive; the pill may need to be stopped 4 weeks beforehand.
• When to seek medical attention: Stop taking Yasmin and contact your doctor immediately if you experience any of the following warning signs of a blood clot: sudden severe chest pain or shortness of breath, coughing up blood, unexplained swelling or pain in a leg, sudden severe headache or vomiting, dizziness or fainting, weakness or numbness of the face, arm, or leg, vision loss or double vision, or jaundice (yellowing of the skin or eyes).
• Disposal: Return unused or expired medication to a pharmacy for safe disposal. Do not flush down the toilet or discard in household waste.

Alternative Medications

• Other combined oral contraceptives (COCs): Pills containing different progestins (e.g., levonorgestrel, desogestrel, norgestimate) and estrogens. Yaz (drospirenone 3 mg / ethinyl estradiol 0.02 mg) has the same progestin at a lower estrogen dose and is also approved for PMDD and acne. Loestrin, Alesse, Marvelon, and Seasonique are among the many COCs available in Canada.
• Progestin‑only contraceptives: The “mini‑pill” (norethindrone or levonorgestrel), the depot‑medroxyprogesterone acetate injection (Depo‑Provera), the etonogestrel implant (Nexplanon), and the levonorgestrel‑releasing intrauterine system (Mirena, Kyleena, Jaydess) are alternatives for women who cannot take estrogen.
• Non‑hormonal options: Copper intrauterine devices (e.g., Nova‑T, Flexi‑T) provide long‑acting, hormone‑free contraception. Barrier methods (male and female condoms, diaphragms) offer STI protection but have higher pregnancy rates with typical use.
• Acne treatment: For women who do not require contraception, topical benzoyl peroxide, topical retinoids, and oral antibiotics or isotretinoin are standard therapies. Spironolactone, a structural relative of drospirenone, is used off‑label for hormonal acne but lacks contraceptive efficacy.
• PMDD management: Selective serotonin reuptake inhibitors (SSRIs) such as sertraline, fluoxetine, and paroxetine are first‑line pharmacologic treatments and may be used continuously or during the luteal phase only. Cognitive‑behavioural therapy and lifestyle modification are also effective.

Clinical Efficacy

The contraceptive efficacy of Yasmin has been established in large multicentre clinical trials. With perfect use (taking every tablet correctly and on time), the Pearl Index (number of pregnancies per 100 woman‑years of use) is approximately 0.09–0.4. With typical use, which accounts for missed tablets and other user errors, the Pearl Index rises to approximately 9. For the treatment of moderate acne vulgaris, three‑ and six‑cycle randomised placebo‑controlled trials demonstrated that Yasmin produced statistically significant reductions in inflammatory and total lesion counts compared with placebo. Improvement in acne was seen within the first few cycles and continued through the treatment period. In women with PMDD, Yasmin (and its lower‑estrogen counterpart Yaz) was superior to placebo in reducing the severity of both emotional (mood swings, irritability, anxiety) and physical (breast tenderness, bloating, headache) symptoms. The efficacy is attributed to the antimineralocorticoid and antiandrogenic properties of drospirenone, which help counteract estrogen‑related fluid retention and androgen‑driven mood changes. The long‑term safety profile, including the slightly elevated VTE risk relative to levonorgestrel‑containing pills, is well described in post‑marketing surveillance and large observational studies.

Important:

Yasmin (drospirenone/ethinyl estradiol) is a prescription combined hormonal contraceptive that should be used only under the supervision of a qualified healthcare professional. It is not to be used during pregnancy or while breastfeeding. Cigarette smoking, particularly in women over 35 years of age, greatly increases the risk of serious cardiovascular events, including heart attack, stroke, and blood clots. Yasmin is contraindicated in women with a history of venous thromboembolism, thrombophilia, migraine with aura, uncontrolled hypertension, liver disease, renal or adrenal insufficiency, or estrogen‑dependent cancers. Drospirenone can raise serum potassium levels; women taking chronic daily treatment with potassium‑elevating medications (ACE inhibitors, angiotensin‑II receptor blockers, potassium‑sparing diuretics, NSAIDs, heparin) should have their potassium checked during the first cycle. Seek emergency medical attention immediately if you develop symptoms of a blood clot, such as sudden severe chest pain, shortness of breath, coughing up blood, unexplained leg pain or swelling, sudden severe headache or weakness on one side of the body. This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Yasmin - Shipping across Canada